Chimeric antigen receptor T-cell (CAR-T) therapy represents a major advancement in cellular immunotherapy, enabling autologous T cells to be genetically modified to recognize tumor-associated antigens and mediate targeted cytotoxicity.
Over the past decade, CAR-T therapy has demonstrated substantial clinical efficacy in several hematologic malignancies. Multiple CAR-T products targeting CD19 or BCMA have received regulatory approval for diseases such as:
- B-cell acute lymphoblastic leukemia (B-ALL)
- Diffuse large B-cell lymphoma (DLBCL)
- Primary mediastinal B-cell lymphoma
- Follicular lymphoma
- Mantle cell lymphoma
- Multiple myeloma
These therapies are now integrated into treatment algorithms in major clinical guidelines, including those from the National Comprehensive Cancer Network and European Society for Medical Oncology.
Given the complexity of CAR-T therapy—ranging from patient selection and manufacturing logistics to management of immune-related toxicities—specialized training programs have become increasingly important for oncologists, hematologists, and translational researchers.
Core Components of CAR-T Training Programs
Training in CAR-T therapy is typically multidisciplinary and includes clinical, laboratory, and translational components. Key elements generally include:
Core Components of CAR-T Training Programs
Training in CAR-T therapy is typically multidisciplinary and includes clinical, laboratory, and translational components. Key elements generally include:
Clinical CAR-T delivery
- Patient eligibility assessment
- Bridging therapy strategies
- Management of treatment-related toxicities
Toxicity management
Particular emphasis is placed on recognition and management of:
- Cytokine release syndrome (CRS)
- Immune effector cell–associated neurotoxicity syndrome (ICANS)
Consensus grading systems and management algorithms are largely derived from guidelines developed by the American Society for Transplantation and Cellular Therapy.
Cell manufacturing and translational research
Trainees are typically exposed to:
- Viral and non-viral gene-transfer technologies
- CAR construct design
- Cellular manufacturing workflows
- Quality control and regulatory requirements
Clinical trial development
Leading programs also provide experience in early-phase clinical trials investigating next-generation cellular therapies.
CAR T-Cell Therapy Success Rate in Acute Lymphoblastic Leukemia in 2026
Leading Global Programs for CAR-T Training
University of Pennsylvania
The University of Pennsylvania is widely regarded as a foundational institution in the clinical development of CAR-T cell therapy. Investigators at Penn, including teams led by Carl June and colleagues, conducted some of the earliest successful clinical studies of CD19-directed CAR-T cells in patients with refractory B-cell malignancies. These studies ultimately contributed to the development of tisagenlecleucel, the first CAR-T therapy approved by the U.S. FDA.
The university’s Center for Cellular Immunotherapies integrates translational immunology research, gene-engineering laboratories, and clinical programs delivering CAR-T therapy. Training opportunities include hematology–oncology fellowships, physician-scientist programs, and laboratory research fellowships focused on T-cell engineering, vector development, and immune-based cancer therapies.
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSK) has played a major role in advancing adoptive cellular therapy and next-generation CAR-T technologies. The institution has contributed to the development of engineered T-cell platforms targeting multiple antigens and continues to lead investigator-initiated trials exploring CAR-T therapy for hematologic malignancies and solid tumors.
MSK’s Cell Therapy and Cell Engineering Facility supports clinical translation of engineered immune cells through integrated manufacturing, translational research laboratories, and early-phase clinical trials. Training pathways are available through hematologic oncology fellowships, immunology research programs, and physician-scientist training tracks emphasizing gene-modified cellular therapies and tumor–immune interactions.
MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center hosts one of the largest and most comprehensive cellular therapy programs worldwide. The institution conducts a wide portfolio of clinical trials investigating CAR-T cell therapies for B-cell malignancies, multiple myeloma, and emerging targets in solid tumors.
MD Anderson’s Institute for Cell Therapy Discovery and Innovation integrates basic immunology, translational engineering, and clinical trial infrastructure. The center provides extensive training opportunities through hematology–oncology fellowships, cellular therapy clinical programs, and translational research laboratories focused on immune-cell engineering, tumor microenvironment biology, and next-generation adoptive cell therapies.
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute, in collaboration with Harvard Medical School and the Broad Institute, is a major academic hub for cellular immunotherapy research. The institute participates in numerous multicenter clinical trials evaluating CAR-T therapies targeting CD19, BCMA, and emerging antigens across hematologic malignancies.
Research programs at Dana-Farber emphasize immune engineering, mechanisms of resistance to cellular therapy, and combination immunotherapy strategies. Training opportunities include hematology-oncology fellowships, postdoctoral programs in tumor immunology, and translational research initiatives focused on improving CAR-T efficacy and safety.
Peter MacCallum Cancer Centre
Peter MacCallum Cancer Centre in Melbourne is one of the leading centers for cellular immunotherapy research in the Asia-Pacific region. The institution combines clinical oncology, immunology, and bioengineering through collaborations with the University of Melbourne and other research institutes.
Peter MacCallum has been involved in the development and clinical evaluation of CAR-T therapies for hematologic malignancies and contributes to international cellular therapy trials. The center provides advanced training opportunities through oncology fellowships, laboratory research programs, and clinical trial participation in adoptive cellular immunotherapy.
Emerging Areas in CAR-T Research
Although current CAR-T approvals are largely confined to hematologic malignancies, ongoing research aims to expand the platform to additional indications. Active areas of investigation include:
- CAR-T therapy targeting solid tumors
- Allogeneic (“off-the-shelf”) cellular therapies
- Gene-edited CAR-T cells using technologies such as CRISPR
- Combination strategies integrating CAR-T with checkpoint inhibitors or targeted therapies
These developments highlight the growing need for clinicians and scientists trained in both the clinical application and translational development of cellular immunotherapies.
Conclusion
CAR-T therapy has transformed the therapeutic landscape for several hematologic malignancies and represents one of the most rapidly evolving areas of cancer immunotherapy.
Training at specialized centers with expertise in cellular therapy provides clinicians and researchers with essential experience in patient management, toxicity monitoring, and translational research. As cellular immunotherapy continues to expand, these programs will remain central to advancing the safe and effective implementation of CAR-T therapy worldwide.
You Can Watch More on OncoDaily Youtube TV